APA
Kamalakaran S., Varadan V., Giercksky Russnes H. E., Levy D., Kendall J., Janevski A., Riggs M., Banerjee N., Synnestvedt M., Schlichting E., Kåresen R., Shama Prasada K., Rotti H., Rao R., Rao L., Eric Tang M., Satyamoorthy K., Lucito R., Wigler M., Dimitrova N., Naume B., Borresen-Dale A. & Hicks J. B. (20110531). DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables. : Molecular oncology.
Chicago
Kamalakaran Sitharthan, Varadan Vinay, Giercksky Russnes Hege E, Levy Dan, Kendall Jude, Janevski Angel, Riggs Michael, Banerjee Nilanjana, Synnestvedt Marit, Schlichting Ellen, Kåresen Rolf, Shama Prasada K, Rotti Harish, Rao Ramachandra, Rao Laxmi, Eric Tang Man-Hung, Satyamoorthy K, Lucito Robert, Wigler Michael, Dimitrova Nevenka, Naume Bjorn, Borresen-Dale Anne-Lise and Hicks James B. 20110531. DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables. : Molecular oncology.
Harvard
Kamalakaran S., Varadan V., Giercksky Russnes H. E., Levy D., Kendall J., Janevski A., Riggs M., Banerjee N., Synnestvedt M., Schlichting E., Kåresen R., Shama Prasada K., Rotti H., Rao R., Rao L., Eric Tang M., Satyamoorthy K., Lucito R., Wigler M., Dimitrova N., Naume B., Borresen-Dale A. and Hicks J. B. (20110531). DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables. : Molecular oncology.
MLA
Kamalakaran Sitharthan, Varadan Vinay, Giercksky Russnes Hege E, Levy Dan, Kendall Jude, Janevski Angel, Riggs Michael, Banerjee Nilanjana, Synnestvedt Marit, Schlichting Ellen, Kåresen Rolf, Shama Prasada K, Rotti Harish, Rao Ramachandra, Rao Laxmi, Eric Tang Man-Hung, Satyamoorthy K, Lucito Robert, Wigler Michael, Dimitrova Nevenka, Naume Bjorn, Borresen-Dale Anne-Lise and Hicks James B. DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables. : Molecular oncology. 20110531.